29 décembre 2024 | International, Aérospatial

Israel and Slovakia sign €560m defence contract for BARAK MX system

The International Defense Cooperation Directorate of the Israel Ministry of Defense (IMOD), SIBAT, has concluded a defence deal with Slovakia.

https://www.army-technology.com/news/israel-slovakia-barak-mx-system/

Sur le même sujet

  • Australian Defence Force Selects GA-ASI MQ-9B for Project Air 7003

    6 décembre 2019 | International, Aérospatial

    Australian Defence Force Selects GA-ASI MQ-9B for Project Air 7003

    San Diego – December 4, 2019 – General Atomics Aeronautical Systems, Inc. (GA‑ASI), the world's leading manufacturer of Remotely Piloted Aircraft Systems (RPAS), has been advised that the Australian Government has selected GA-ASI's MQ-9B SkyGuardian® variant to provide the Armed RPAS for the Australian Defence Force (ADF) under Project Air 7003. This follows the Government's announcement in November 2018 that GA-ASI would provide Armed RPAS to the ADF. The ADF expects to take first delivery in the early 2020s. “We have worked closely with the ADF to determine the right RPAS to meet their needs,” said Linden Blue, CEO, GA-ASI. “MQ-9B will provide the all-weather, multi-mission support, and interoperability that the ADF requires. We look forward to working closely with our Australian industry partners to provide a highly capable RPAS to the ADF, while creating high-tech jobs in Australia.” The ADF joins other top-tier military forces in choosing a GA-ASI RPAS because of its proven multi-role combat performance. MQ-9B is part of GA-ASI's Predator® series of RPAS, which is the world's most trusted and capable armed Medium-altitude, Long-endurance (MALE) RPAS, and hails from a family of aircraft that has flown more than six million flight hours. The UK Royal Air Force (RAF) is acquiring the MQ-9B as part of its Protector RG Mk1 program and is scheduled for first delivery in the early 2020s. The Government of Belgium has approved Belgian Defense to negotiate for the acquisition of MQ-9B to meet the nation's RPA requirements. MQ-9B development is the result of a five-year, company funded program to deliver an unmanned aircraft system to meet the stringent airworthiness type-certification requirements of NATO and civil aviation authorities throughout the world. MQ-9B is provisioned for the GA-ASI-developed Detect and Avoid (DAA) system, which consists of air-to-air radar, Traffic alert and Collision Avoidance System (TCAS II), and Automatic Dependent Surveillance-Broadcast (ADS-B). The MQ-9B is built for all-weather performance with lightning protection, damage tolerance, and de-icing system. GA-ASI announced its intention to offer a MALE RPAS to the ADF during AVALON 2017 with the launch of Team Reaper Australia, a robust group of Australian industry partners. The team currently consists of ten world-class Australian companies providing a range of innovative sensor, communication, manufacturing and life-cycle support capabilities including Cobham (lead industry partner), CAE, Raytheon, Flight Data Systems, TAE Aerospace, Quickstep, AirSpeed, Collins Aerospace, Ultra, and SentientVision. Hi-resolution images of the MQ-9B SkyGuardian are available to qualified media outlets from the GA-ASI media contact list. About GA-ASI General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Remotely Piloted Aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With nearly 6 million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com Predator, SkyGuardian and Lynx are registered trademarks of General Atomics Aeronautical Systems, Inc. For more information contact: GA-ASI Media Relation General Atomics Aeronautical Systems, Inc. +1 (858) 524-8108 ASI-MediaRelations@ga-asi.com View source version on GA-ASI: http://www.ga-asi.com/australian-defence-force-selects-ga-asi-mq-9b-for-project-air-7003

  • Les industriels du programme Eurodrone s’accordent sur les performances

    29 mai 2020 | International, Aérospatial

    Les industriels du programme Eurodrone s’accordent sur les performances

    Les industriels du programme Eurodrone, à savoir Airbus, Dassault Aviation et Leonardo, et le ministère français des Armées sont parvenus à un accord sur les performances de l'appareil MALE. « Les performances satisfont pour une très large partie les besoins militaires », explique le ministère des Armées à La Tribune. L'Eurodrone doit voler en 2027 pour une mise en service prévue en 2027/2028. La Tribune du 28 mai 2020

  • Reinventing Drug Discovery and Development for Military Needs

    30 novembre 2018 | International,

    Reinventing Drug Discovery and Development for Military Needs

    Flying at 50,000 feet, diving deep in the ocean, or hiking for miles with gear through extreme climates, military service members face conditions that place unique burdens on their individual physiology. The potential exists to develop pharmacological interventions to help service members complete their toughest missions more safely and efficiently, and then recover more quickly and without adverse effects, but those interventions must work on complex physiological systems in the human body. They will not be realized under the prevailing system of drug discovery and development with its focus on engaging single molecular targets. DARPA created the Panacea program to pursue the means of rapidly discovering, designing, and validating new, multi-target drugs that work with the body's complexity to better support the physiological resilience and recovery of military service members. The premise of Panacea is that the physiological systems of the human body work in complex and highly integrated ways. Drugs exert effects on our bodies by physically interacting with and changing the functional state of biomolecules that govern the functions of cells and tissues. Most drugs target proteins, which are the principle cellular workhorses. Ideally, drugs would target multiple proteins simultaneously to exert precise, network-level effects. One major problem facing the drug development community is that the functional proteome — the complete collection of proteins and their roles in signaling networks — is largely dark to science. Despite being able to identify many of the proteins within a cell, researchers do not have a firm grasp on everything those proteins do and how they interact to affect physiology. Due to this sparsity of structural and functional knowledge, the state of the art in drug development — what Panacea seeks to transform — is to engage only a very small fraction of known protein targets to achieve an effect. In fact, today's approach to drug design singles out individual proteins in certain cells. That hyper-specificity is an attempt to minimize the risk of side effects and speed time to market, but it also yields a thin stream of drugs, many of which have similar mechanisms and relatively muted effectiveness compared to what might be achieved using a multi-target, systems-based approach. “The current roster of drugs approved by the U.S. Food and Drug Administration only targets about 549 proteins, yet the body can produce more than six million different protein variants,” said Tristan McClure-Begley, the Panacea program manager. “The opportunity space for pharmacological intervention is vast and effectively untapped, but to access it we need new technology for understanding and targeting the human functional proteome.” Panacea will address the lack of functional knowledge about the proteome. DARPA's call to the research community is to consider complex physiological conditions relevant to military service members — for instance, metabolic stress during extreme endurance missions or pain and inflammation after injury; investigate the molecular mechanisms underlying those conditions; identify multiple, key molecular targets involved; and develop novel medicinal chemistry approaches to synthesize interventions that modulate those targets. DARPA believes that multi-target drugs will deliver safer and more efficacious solutions to military requirements for readiness and recovery over state-of-the-art interventions. “Many of the most successful drugs produced in the past were found rather than made, and we knew what they did long before we knew how they did it,” McClure-Begley said. “To deliver improved interventions, we need to get to a place where we can investigate all of the potential proteins at play for a given condition and then prioritize sets of protein targets and signaling networks to effectively modulate physiological systems, regardless of what prior knowledge exists about those targets.” The Panacea program aims to generate initial proof of concept for this new direction in drug discovery and development. Research will primarily involve animal models, human cell derived organoids, and high-throughput cell culture models. However, to support eventual transition to humans, DARPA will work with federal agencies to develop a regulatory pathway for future medical use. By the end of the five-year program, DARPA will require teams to submit novel drug candidates to the U.S. Food and Drug Administration for review as an Investigational New Drug or for Compassionate Use. DARPA will hold a Proposers Day on December 14, 2018, in Arlington, Virginia, to provide more information about Panacea and answer questions from potential proposers. For details of the event, including registration requirements, visit https://go.usa.gov/xP6hD. A forthcoming Broad Agency Announcement will fully describe the program structure and objectives. https://www.darpa.mil/news-events/2018-11-28

Toutes les nouvelles